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Introduction
Apixaban (Eliquis®) is a direct and competitive inhibitor
of factor FXa that is approved for thrombosis prophylaxis
after hip and knee replacement surgery, in non-valvular
atrial fibrillation and venous thromboembolic events
therapy [1]. In cases of severe hemorrhages there is no
approved specific antidote available to reverse the effect
of apixaban yet. Previous animal and in vitro studies [2,3]
with supratherapeutic concentrations of apixaban (200ng
ml-1) have shown that activated prothrombin complex
concentrate (aPCC) and recombinant factor VIIa (rFVIIa)
have a greater effect in reversing the effect of apixaban
than prothrombin complex concentrate (PCC). The effect
of these non-specific hemostatic agents for reversal of
apixaban concentrations measured in patients after pro-
phylactic doses (maximum observed plasma concentra-
tion 62 ng ml-1 [4]) remains unclear.
Objectives
Evaluation of the efficacy of PCC, aPCC and rFVIIa for
reversal of prophylactic concentration of apixaban
induced alterations in hemostasis.
Methods
Blood samples from 10 healthy volunteers were spiked
with apixaban in a corresponding dose of 2.5 mg twice
daily (4) and clinically relevant concentrations of PCC:
Cofact®: 25 IU kg-1 (0,35 IU ml-1), aPCC: FEIBA® 25 IU
kg-1 (0,35 IU ml-1) and rFVIIa: Novoseven® 90µg kg-1
(1 µg ml-1). Tests were performed including thromboelas-
tometry, prothrombin time (PT) and activated partial
thromboplastin (aPTT). Statistical analysis was performed
using non-parametric Wilcoxon pair-wise test.
Results
Apix-apixaban; Data are median (95% confidence interval).
*p < 0,05 vs. Control, #p < 0,05 vs. apix
Prolongations in measured latency parameters were cor-
rected by the different concentrates with variable efficacies
(rFVIIa≥aPCC>PCC). Addition of aPCC and rFVIIa to the
spiked blood samples leads to overcorrection of PT, aPTT
and CT-EXTEM.
Conclusions
Recombinant FVIIa and aPCC have the potential to
restore the induced alterations in hemostasis of apixaban
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Table 1
Control apix PCC 0,35IU ml-1 aPCC 0,35IU ml-1 rFVIIa 1µg ml-1
apix ng ml-1 0 53 55 53 53
CT-EXTEM (s) 70 78 78# 57*# 52*#
aPTT (s) 34,6 37,0* 37,3*# 32,9*# 29,5*#
PT (s) 13,7 14,0* 13,0*# 11,5*# 9,0*#
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in prophylactic dose in vitro. PCC showed partial effects
only. The reversal effects of activated factor concentrates
tend to overcorrection, which might be a risk for throm-
botic events.
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